• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Hologic 3Q revenues and backlog soar

Article

Revenues boomed for Hologic last quarter. In the three-month period ended June 26, the provider of women's diagnostic imaging systems brought in $59,225,000, a 13% increase compared with revenues of $52,332,000 in the same quarter 2003. Net income was

Revenues boomed for Hologic last quarter. In the three-month period ended June 26, the provider of women's diagnostic imaging systems brought in $59,225,000, a 13% increase compared with revenues of $52,332,000 in the same quarter 2003. Net income was $3,325,000, or 15¢ per diluted share, compared with net income of $1,019,000 or 5¢ per diluted share in the previous year's period. Driving the improvements was a continued shift in product sales to the higher margin Selenia digital mammography system. Hologic installed 37 Selenia full-field digital mammography systems during the third quarter. At the end of 3Q, 80 Selenias were on backlog, and total product backlog exceeded $58 million.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.